Research programme: HIV protease inhibitors - Pfizer
Latest Information Update: 23 Jul 2002
At a glance
- Originator Pfizer
- Mechanism of Action HIV protease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 12 Sep 2000 New profile
- 12 Sep 2000 Preclinical development for HIV-1 infections in USA (Unknown route)